

POXEL S.A.

ISIN:
FR0012432516
 WKN: -

Overview

2022/09/29 17:30:00

Price

1.557 EUR

Difference  -1.64% (-0.03)

General attributes

| | |
|----------------|---|
| ISIN | FR0012432516 |
| Symbol | POXEL |
| Exchange | London Stock Exchange European Trade Reporting |
| Currency | EUR |
| Sector | Other |
| Security type | Stock |
| Market cap (m) | 46 EUR |
| Benchmark | CAC 40 INDEX |

Market data

| | |
|-------------------|--------------------|
| Bid (Bid size) | 1.48 EUR (10,000) |
| Ask (Ask size) | 1.634 EUR (10,000) |
| Open | 1.589 EUR |
| High | 1.589 EUR |
| Low | 1.557 EUR |
| Close (prev. day) | 1.583 EUR |
| VWAP | 6.64019 EUR |
| Volume (pcs) | - |
| Trading volume | - |
| Number of trades | 2 |
| Last size | - |

Futures and Options

| | |
|-----------------|---|
| Related Futures | - |
| Related Options | - |

PDF Downloads

Annual report: POXEL S.A. 

5Y



Information about previous performance does not guarantee future performance.
 Source: FactSet

Recent research

| on sector | | on market | |
|------------|---|-------------------------------|---|
| Date | | Headline | Download |
| 2022/09/26 |  | Global Equity Ratings |  |
| 2022/09/26 |  | Aktienempfehlungen Global |  |
| 2022/09/19 |  | Aktienempfehlungen Österreich |  |
| 2022/09/16 |  | Equity Weekly |  |
| 2022/09/09 |  | Equity Weekly |  |

Details

2022/09/29 17:30:00

Price

1.557 EUR

Difference  -1.64% (-0.03)

General attributes

| | |
|----------------|---|
| ISIN | FR0012432516 |
| Symbol | POXEL |
| Exchange | London Stock Exchange European Trade Reporting |
| Currency | EUR |
| Sector | Other |
| Security type | Stock |
| Market cap (m) | 46 EUR |
| Benchmark | CAC 40 INDEX |

Market data

| | |
|-------------------|--------------------|
| Bid (Bid size) | 1.48 EUR (10,000) |
| Ask (Ask size) | 1.634 EUR (10,000) |
| Open | 1.589 EUR |
| High | 1.589 EUR |
| Low | 1.557 EUR |
| Close (prev. day) | 1.583 EUR |
| VWAP | 6.64019 EUR |
| Volume (pcs) | - |
| Trading volume | - |
| Number of trades | 2 |
| Last size | - |

Performance and Risk

| | 6M | 1Y | 3Y |
|-------------|---------|---------|-------|
| Perf (%) | -33.83% | -73.89% | - |
| Perf (abs.) | -0.80 | -4.41 | - |
| Beta | 1.13 | 1.18 | 0.98 |
| Volatility | 62.67 | 63.64 | 59.73 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 1.613 EUR (0) |
| Ø price 30 days Ø volume 30 days (pcs.) | 2.127 EUR (0) |
| Ø price 100 days Ø volume 100 days (pcs.) | 1.917 EUR (0) |
| Ø price 250 days Ø volume 250 days (pcs.) | 3.244 EUR (0) |
| YTD High date | 5.101 EUR (2022/01/04) |
| YTD Low date | 1.530 EUR (2022/09/26) |
| 52 Weeks High date | 6.105 EUR (2021/10/20) |
| 52 Weeks Low date | 1.530 EUR (2022/09/26) |

All listings for POXEL S.A.

| Exchange  | Date | Time | Price | Trading volume (mio.) | Number of trades |
|--|------------|-------|-----------|-----------------------|------------------|
| Stuttgart | 2022/09/29 | 16:48 | 1.552 EUR | 0.00 | 12 |
| Munich | 2022/09/29 | 08:03 | 1.63 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2022/09/29 | 17:30 | 1.557 EUR | 0.00 | 2 |
| Frankfurt | 2022/09/29 | 17:20 | 1.562 EUR | 0.00 | 7 |
| FINRA other OTC Issues | 2022/ | 17:40 | 2.60 USD | 0.00 | 1 |

| | | | | | | |
|----------------|----------------|-------|-----------|------|--|-----|
| | 08/16 | | | | | |
| Euronext Paris | 2022/ 09/29 | 17:35 | 1.58 EUR | 0.08 | | 118 |
| Berlin | 2022/ 09/29 | 08:03 | 1.548 EUR | 0.00 | | 1 |

Company profile

Company Logo



Contact Details

POXEL SA

--

259/261, Avenue Jean Jaurès - 69007 Lyon

Telefon: 33-4-37-37-20-12

Fax: 33-4-37-70-88-15

E-mail: -

PDF Downloads

Annual report: POXEL S.A.



Company Profile

Poxel SA operates as a clinical-stage biopharmaceutical company. The firm focuses on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). Its drug candidates include Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.

Board of directors

| | |
|-----------------------|-------------------------------|
| Pierre Legault | Chairman of Supervisory Board |
| Janice Bourque | Member of Supervisory Board |
| Kumi Sato | Member of Supervisory Board |
| Mohammed Khoso Baluch | Member of Supervisory Board |
| Pascale Boissel | Member of Supervisory Board |
| Richard Kender | Member of Supervisory Board |